OKYO Pharma Enrolls First Patients in Phase 3 NEPTUNE Trial
OKYO Pharma has enrolled the first patients in its Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain. This registrational study includes sites in the U.S. and Europe.
OKYO Pharma has enrolled the first patients in its Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain. This registrational study includes sites in the U.S. and Europe.